• KRAS G12D expression in mouse lung myeloid cells induces pulmonary LCH-like neoplasms.
• KRAS G12D expression in mouse lung myeloid cells induces pulmonary LCH-like neoplasms.
• KRAS G12D -induced LCH-like neoplasms are sensitive to in vivo treatment with 3-hydroxy-3-methylglutaryl coenzyme A inhibitor Q : 7 atorvastatin.
Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm associated with somatic mutations in the genes involved in the RAF/MEK/extracellular signal-regulated kinase (ERK) signaling 
Introduction
Langerhans cell histiocytosis (LCH) is a rare disorder characterized by abnormal growth of CD1a 1 S100 1 histiocytes that share some characteristics with epidermal Langerhans cells (LCs).
1,2 Multiple organs, including the skin, bone, liver, and lung, are affected in LCH either as a multisystem or single-organ disease, and hematopoietic organ involvement has been shown to be a feature of high-risk diseases. 1 Pulmonary involvement occurs either in isolation or as part of multisystem diseases, though .85% cases of pulmonary LCH have been reported as single-organ involvement. 3 Recent discoveries of somatic mutations in the genes involved in the RAS/RAF/MEK/extracellular signal-regulated kinase (ERK) pathway have unveiled that LCH pathogenesis is driven by neoplastic transformation associated with deregulated ERK pathway activation. [4] [5] [6] [7] [8] [9] The BRAF T1799A mutation, leading to BRAF V600E oncoprotein expression, is most common in LCH, 4 whereas other genes in the ERK pathway, including ARAF 5 and MAP2K1, 6, 7 have been also reported as mutational targets. Furthermore, NRAS 8 and KRAS 9 mutations, leading to NRAS Q61K/R and KRAS G12V/A oncoprotein expression, respectively, have been identified uniquely in pulmonary LCH cases, suggesting organ-specific contribution of oncogenic RAS to the pathogenesis of LCH.
Both LCs and lesional LCH cells express Langerin (also known as CD207), a C-type lectin that contributes to the formation of Birbeck granules in LCs/LCH cells. 10, 11 However, Langerin expression is not restricted to LCs: it is also detected in subsets of dendritic cells (DCs), including CD103
1 DCs. 12 A previous study utilizing genetically engineered mouse (GEM) models demonstrated that BRAF V600E expression in CD11c 1 or Langerin 1 DC-lineage cells is sufficient to drive LCH-like pathology in mice, proposing that LCH could originate from CD11c
1 DC precursors or Langerin 1 mature DCs. 13 However, it is currently unclear whether Langerin promoter-driven Cre recombinase (Cre) expression used in the model 13 
F4/80
1 phenotype, 12 arise largely from embryonic/fetal precursors, including yolk-sac-derived myeloid progenitors 14, 15 and fetal liver monocytes, 16 in a CSF1R (also known as MCSFR or CD115)-dependent manner. 17, 18 LC precursors distributed in the embryonic epidermis express CD11c and Langerin immediately after birth, 19 suggesting that BRAF V600E induction in the GEM models above 13 could start during the first week of life at the latest. Importantly, the majority of human pulmonary LCH cases are adult onset, in contrast to multisystem LCH that is predominantly diagnosed during childhood. 20 Therefore, animal models recapitulating the adult-onset pathology in the lung are preferred in order to study the pathogenesis of pulmonary LCH that could be considerably different from multisystem LCH. Conditional knockin mice expressing KRAS G12D following Cre expression have been previously reported and extensively used to study The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. 21 has been previously used to study lung adenocarcinoma, somewhat unexpectedly, we found that this model developed mixed neoplasms with hematopoietic and epithelial components. Our investigations confirm that the hematopoietic pathology is driven by KRAS G12D expression in specific myeloid population(s) in the lung, recapitulating some aspects of pulmonary LCH. Using this model as a therapeutic platform, we found that the pulmonary LCH-like disease is sensitive to in vivo treatment with atorvastatin, suggesting therapeutic potential of statins for the treatment of RAS-driven pulmonary LCH.
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Materials and methods

Animals
Animal experiments were performed under UK Home Office License authority. Kras
LSL-G12D
, Braf
LSL-V600E
, and their recombined alleles were genotyped as described. 22, 23 hematoxylin-and-eosin (H&E) staining and immunohistochemistry (IHC) as described. 22 Antibodies used for IHC are described in the supplemental Methods (available at the Blood Web site).
Immunofluorescence, immunoblotting, flow cytometry, and cell sorting Paraformaldehyde-fixed, Triton-X-permeabilized cells were stained for Mac2, and blocked for endogenous biotin as described. 24 Then, the cells were stained with anti-CD207-biotin antibody (1:100; eBioscience), followed by Alexa Fluor 488-conjugated streptavidin (Invitrogen) staining (1:2000) . Images were obtained and processed as described. 24 Protein lysates were prepared by solving frozen tissues into 13 sodium dodecyl sulfate sample buffer or cultured cells into NP40 buffer, and analyzed by western blotting as described. 25, 26 Cell surface markers were analyzed by flow cytometry as described. 24 For in vitro 5-bromo-29-deoxyuridine (BrdU) incorporation, cells labeled with 10 mM BrdU for 18 hours were analyzed as described. 24 For cell sorting, lung tissues digested by 30-minute collagenase/DNase treatment were stained for cell surface markers as described, 24 and sorted using FACSAria II (BD Biosciences). Antibodies used are described in the supplemental Methods.
Cell cultures
Cell cultures were performed essentially as described. 24 Detailed methods are described in the supplemental Methods.
In vitro adenoviral infection and limiting dilution culture
Cells from KRAS LSL-G12D lungs were plated at 2 3 10 5 per well to 10 3 10 5 per well, and infected with adenoviral vectors at a multiplicity of infection equal to (MOI) 100. After 1 week of infection, media containing the virus were removed, and the cultures were maintained in Dulbecco modified Eagle medium/10% fetal calf serum with half media changes every 3 to 5 days without disturbing nonadherent cells. Limiting dilution analysis was performed using ELDA software. 27 Coculture of sorted myeloid cells with lung fibroblast feeders A total of 1 3 10 5 sorted myeloid cells were infected with adenovirus vectors at MOI 5 100 in Dulbecco modified Eagle medium/10% fetal calf serum for 24 hours, and transferred onto fibroblast feeders established by serial passages of wild-type lung cells. On day 7, media containing the virus were removed, and the cultures were maintained as described for limiting dilution culture.
Statistics
Comparison between any 2 groups was performed by the unpaired Student t test. x 2 tests were used to statistically evaluate the differences in limiting dilution cultures.
Results
Lung-restricted KRAS
G12D expression induces accumulation of
Nasal inhalation of AdCMVCre into KRAS LSL-G12D/1 mice has been widely exploited to investigate lung carcinogenic processes. Although AdCMVCre could induce oncogene expression in any type of cell when successfully infected, nasal inhalation of 10 5 plaque-forming units Q : 10 (pfu) AdCMVCre preferentially promotes epithelial transformation in this model. 21 To investigate whether higher viral doses could induce neoplastic transformation of other cell types, we administrated 3 3 10 7 pfu AdCMVCre into KRAS LSL-G12D/1 mice by nasal inhalation (referred to as AdCre/KRAS G12D mice hereafter), and AdCre/ KRAS G12D mice exhibiting severe respiratory symptoms at 4 to 6 months following nasal inhalation were analyzed histologically. As expected, a number of solid mass lesions containing epithelial components were observed, but these lesions were frequently intertwined with round cells with a less eosinophilic cytoplasm Q : 11
( Figure 1A ). In addition, distal alveolar spaces were occasionally filled with similar round cells, mimicking the pathology of desquamative interstitial pneumonia (DIP) ( Figure 1A ). The round cells in both solid and DIP-like lesions were positive for S100, a marker for LCH 2 ( Figure 1A ).
Because the morphology of the round cells observed in AdCre/ KRAS G12D lungs was suggestive of their hematopoietic origin, we analyzed hematopoietic compartments in the AdCre/KRAS G12D lungs using flow cytometry. Compared with KRAS 1/1 mice nasally delivered with AdCMVCre (referred to as AdCre/KRAS WT mice hereafter), the percentage of CD11b 
CD11c
1 population (Figure 2A) , indicating that the accumulation of CD11c 1 cells was driven by their KRAS G12D expression. Morphologically, the sorted CD11c population was composed of smaller round cells with a basophilic cytoplasm and larger macrophage-like cells ( Figure 2B ). Monocytes or neutrophils with typical morphologies were not identified. Because of the F4/80 1 phenotype and histological findings that are consistent with LC/ LCH characteristics ( Figure 1A) , 2, 12, 14, 28, 29 we next performed CD207 immunostaining of enriched CD11c 1 cells combined with a myeloid marker MAC2. 30 We found that most cells showed reticular 1 cell accumulation in the AdCre/KRAS G12D lung was detected by IHC, and increased CD207 protein expression was confirmed by immunoblotting ( Figure 2C ). Figure 3A ), indicating that they were mitotically inactive. Interestingly, some BrdU incorporation was detected in CD11c dim cells ( Figure 3A ), but they failed to grow in long-term culture (data not shown). In contrast, when CD11c high cells were removed by selective adhesion to plastic plates and the resulting "CD11c-depleted" nonadherent cells were cultured, floating cell clusters and endothelial (CD31 When the floating cells were replated, they altered their morphology within 48 hours. Half of the cells showed LC-like dendritic morphology whereas one-third had a macrophage-like round/amoeboid morphology ( Figure 3D ). Plasma membrane CD207 expression and nuclear MAC2 localization were characteristic of LC-like cells and were not observed in the macrophage-like cells ( Figure 3D ). These in vitro data suggest the presence of proliferative precursors in the AdCre/ KRAS G12D Figure 4A -B) in a similar manner to the AdCre/KRAS G12D lung cultures ( Figure 3B) . When the plating cell number was increased to 1 3 10 6 , 75% of the culture produced cell clusters, by which the frequency of MPICs was estimated as 1 in 0.83 3 10 6 lung cells (95% confidence interval, 1 in 1.39 3 10 6 to 1 in 0.50 3 10 6 ) ( Figure 4C ). Floating cell clusters developing in these cultures showed clear KRAS G12D recombination ( Figure 4D ). In contrast, cells infected with control vectors only developed mixed cultures with macrophage-like cells and fibroblasts ( Figure 4A-B) , indicating that KRAS G12D expression was essential for the aberrant growth of small round cells forming cell clusters. Half of AdCMVCre-infected cultures plated at 2 3 10 5 cells per well also developed macrophage/fibroblast mixed cultures ( Figure 4A-B) , and floating macrophages collected from the cultures showed KRAS G12D recombination ( Figure 4D ), suggesting that KRAS G12D expression in lung macrophages might not be sufficient for initiating the development of cluster-forming cells.
Floating cell clusters were maintained in culture for 7 weeks, and their CD11c
1
F4/80
1 phenotype was confirmed ( Figure 4E ). Morphological changes to LC-like cells were also observed upon replating ( Figure 4F ), but plasma membrane CD207 staining or MAC2 nuclear translocation was rarely detected in this condition. In the in vitro AdCMVCre infection culture, neither endothelial networks nor epithelial cells were developed. Such differences in the nonhematopoietic components observed following in vivo and in vitro KRAS G12D induction might affect the CD207/MAC2 phenotype of the developed LC-like cells. Figure 5A-B) . KRAS G12D recombination was undetectable in Fr-3/4 cells that could not survive in this condition, but AdCMVCre-infected Fr-1/2 cells showed weak KRAS G12D recombination ( Figure 5B ). When cultured without feeders, infected Fr-1/2 cells were viable for a couple of days, but eventually died within 10 days without showing any signs of active growth. However, AdCMVCre-infected Fr-2 cells proliferated to form round cell clusters on fibroblast feeders ( Figure 5C) mice (referred to as AdCre/BRAF V600E mice hereafter), and lung tissues were histologically analyzed at 4 months following AdCMVCre infection. In contrast to AdCre/KRAS G12D mice, well-demarcated papillary adenomas accompanied by myeloid cells in the microenvironment developed, especially in adenoma-rich areas ( Figure 6A left) as we have previously reported. 24 On the other hand, alveolar structures in adenoma-free areas were largely intact without developing DIP-like lesions (Figure 6A right) .
Although we previously reported reactive myeloid cell accumulation in the BRAF V600E model induced by spontaneous activation of CreER, 24 the myeloid cells similarly accumulating in the AdCre/ BRAF V600E lung were not formally proven to be nonneoplastic. To address this, we sorted hematopoietic subpopulations from the AdCre/ BRAF V600E lung, and BRAF recombination was examined. Similarly to the AdCre/KRAS G12D lung (Figure 2A ), 3 distinct hematopoietic populations were identified, but the CD11c 1 population in the AdCre/BRAF V600E lung showed only subtle recombination of the BRAF V600E allele (Figure 6B ), confirming that CD11c 1 cells in the BRAF model were largely nonneoplastic. These data demonstrate that BRAF V600E expression in lung-resident myeloid cells by nasal delivery of AdCMVCre is not sufficient for promoting myeloid neoplasms as seen in the AdCre/KRAS G12D lung.
In vivo statin treatment inhibits accumulation of CD11c 1 cells in the AdCre/KRAS G12D lung
Isoprenylation of RAS proteins promotes their association with the plasma membrane where the proteins are activated. 42 Consistently, genetic modifications inhibiting RAS prenylation have been reported to ameliorate KRAS-driven myeloproliferative disorders. 43, 44 Therefore, we sought to investigate whether chemical inhibition of protein prenylation suppresses myeloid neoplasm developing in the AdCre/ KRAS G12D mice. Because isoprenoid lipids synthesized through the mevalonate pathway are required for RAS prenylation, 42 we used atorvastatin, an 3-hydroxy-3-methylglutaryl coenzyme
Q : 13
A reductase inhibitor that suppresses the mevalonate pathway upstream of isoprenoid lipid production. AdCre/KRAS G12D lung cultures treated with 3.3 mM atorvastatin showed significant reduction of proliferating CD45
1 cells compared with vehicle control cultures ( Figure 7A ). This antiproliferative effect was not associated with differentiation induction because CD11c and F4/80 expression was rather suppressed by atorvastatin ( Figure 7B ). Our biochemical analysis of CD11c-enriched AdCre/KRAS G12D lung cells treated with atorvastatin showed decreased AKT, but not ERK, phosphorylation ( Figure 7C ), suggesting that inhibition of RAS prenylation inhibits RAS interaction with phosphatidylinositol 3-kinase (PI3K), as reported for marrow-derived macrophages. 45 Of note, poly (ADP-ribose) polymerase 1 (PARP-1) cleavage Q : 14 was also induced by atorvastatin ( Figure 7C ), indicating that apoptosis of atorvastatin-treated CD11c 1 cells might contribute to the reduced CD11c levels in atorvastatin cultures ( Figure 7B ).
The in vitro effects of atorvastatin prompted us to target the myeloid neoplasm in vivo. We thus treated AdCre/KRAS G12D mice with atorvastatin for 5 weeks. In drug-treated animals, the DIP-like pathology was robustly improved, though some mass lesions, mainly composed of epithelial components, remained in the periphery of the lung ( Figure 7D ). Quantitative analysis using flow cytometry confirmed up to 70% reduction of CD11c
1
F4/80
1 cells by atorvastatin, but no significant reduction was observed in other cells ( Figure 7E ). These data suggest the potential of statins as chemotherapeutic agents against RAS-mutated pulmonary LCH.
Discussion
Due to its distinct clinical characteristics, pulmonary LCH requires management/therapeutic strategies different from multisystem LCH. 46 To better understand the pathogenesis of pulmonary LCH, and broaden therapeutic options for patients struggling with advanced diseases, development of animal models recapitulating the human disease is essential. In the present study, we found that adenoviral induction of KRAS G12D expression in lung-resident myeloid cells promotes pulmonary LCH-like neoplasm in mice, and that the pathology can be ameliorated by in vivo administration of atorvastatin, a cholesterollowering drug widely used in the clinic. These data shed light on the potential cellular origin and genetic/molecular pathogenesis of pulmonary LCH, and provide a rationale to explore the therapeutic potential of statins against subsets of pulmonary LCH.
As far as we know, this is the first demonstration that nasal delivery of AdCMVCre to the KRAS LSL-G12D mouse lung can induce hematopoietic neoplasms. Our data show that nasal delivery of AdCMVCre at relatively high doses is required for inducing myeloid neoplasms, likely due to relatively few cells in the lung initiating neoplastic myeloid growth (Figure 4) . However, the lung pathology induced by high-dose AdCMVCre is complex, with hematopoietic phenotypes coexisting with alveolar and bronchiolar neoplasms. These factors may have collectively contributed to the fact that KRAS G12D -induced neoplastic transformation of lung-resident myeloid cells in this model has not been previously appreciated.
To our surprise, the majority of pathogenic CD11c high cells in the AdCre/KRAS G12D lung were found to be mitotically inactive ( Figure 3A ), though this is consistent with a previous study showing nonproliferative lesional cells in human pulmonary LCH. 47 Instead, proliferating CD45
1 cells expressing variable levels of CD11c developed in culture, suggesting that proliferating precursors for CD11c transforming growth factor b1 (TGFb1). 48 The CD11c-depleted culture was composed of not only hematopoietic, but also epithelial, fibroblastic, and endothelial cells ( Figure 3B ) and our preliminary analysis detected TGFb1 in the culture media Q : 16 (T.K. and C. A.P., unpublished data). Further investigations to identify the cellular source(s) for the secreted TGFb1 are currently under way.
Although our data suggest that CD11b int CD11c dim Gr1 2 monocytes are the major cellular targets of KRAS G12D -induced transformation in our model, the in vitro infection efficiency of AdCMVCre into this population was very low ( Figure 5B ). This could be due to the low-level expression of av integrins that mediate adenovirus internalization. 49 Granulocyte-macrophage colony-stimulating factor Q : 17 (GMCSF) stimulation of human monocytes reportedly induces av integrin expression, leading to improved adenoviral gene delivery, 49 whereas alveolar epithelial cells are the major GMCSF-producing cells in mouse lungs. 50 Alveolar epithelium-derived GMCSF may induce av integrin expression in vivo in lung-resident monocytes, making them more susceptible to adenoviral infection. BRAF is frequently mutated in human pulmonary LCH (24%-63%) 4, 8, 9, [39] [40] [41] with much higher prevalence than KRAS (8%), 9 though NRAS mutations could be more common than KRAS.
8 But unexpectedly, a pulmonary LCH-like neoplasm was not observed in our AdCre/BRAF model ( Figure 6 ). This may be explained by different cell populations initiating the BRAF-induced pathology. 
Gr1
2 monocytes, as suggested by our atorvastatin data ( Figure 7C ).
Using our model as a platform for preclinical evaluation, we identified antitumor effects of atorvastatin against KRAS G12D -driven pulmonary LCH-like neoplasm ( Figure 7 ). Antigrowth effects of statins on tumor cells are thought to be attributable, at least in part, to inhibition of RAS family small GTPases. 51 Our biochemical data ( Figure 7C ) suggest that atorvastatin inhibits prenyl-dependent association between KRAS and PI3K as reported in simvastatin-treated human peripheral blood mononuclear cells
Q : 18
. 45 Intriguingly, PIK3CA/BRAF comutations have been identified in Erdheim-Chester disease, a histiocytic disorder closely related to LCH, 52 suggesting that cooperative activation of the MEK/ERK and PI3K pathways could contribute to the pathogenesis of histiocytic neoplasms. Although cancer-associated PIK3CA mutations are rare in LCH, 53 we previously reported contribution of autocrine PI3K activation to the aberrant growth of BRAF V600E -expressing mouse HSPCs. 25 Autocrine PI3K activation may also contribute to the pathogenesis of human multisystem LCH, in which marrow CD34 1 HSPCs reportedly harbor BRAF mutations. 13 In this regard, PI3K-targeted therapeutics may be beneficial for treating refractory LCH, not restricted to RAS-mutated pulmonary diseases but including BRAFmutated multisystem diseases.
We exploited an autochthonous GEM model to investigate how KRAS G12D expression in the lung affects lung-resident myeloid cells in a spatiotemporally controlled manner, leading to a unique opportunity to model pulmonary LCH. However, the clinical relevance of our preclinical study has yet to be fully explored in the clinical setting, though recent discoveries of RAS mutations in human pulmonary LCH are consistent with our findings. Future investigations of pulmonary LCH cases with regard to correlation between statin use and clinical outcomes/RAS mutation status would provide valuable information. Notably, a recent report of a phase 2 clinical trial of pan-AKT inhibitor afuresertib for LCH patients, including 7 evaluable cases with pulmonary involvement, demonstrated that AKT inhibition exerts limited efficacy against pulmonary LCH patients. 54 Because AKT inhibition induces feedback activation of PI3K, 55 which could signal through AKT-independent downstream pathways, 56 AKT may not be an optimal target to suppress the PI3K pathway. Direct inhibition of PI3K isoform(s), rather than AKT inhibitors, would be warranted in future clinical trials for pulmonary LCH patients.
